Pharma Mar (OTCMKTS:PHMMF) Shares Gap Up – Still a Buy?

Pharma Mar (OTCMKTS:PHMMF)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $86.0858, but opened at $97.3585. Pharma Mar shares last traded at $97.3585, with a volume of 166 shares.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PHMMF. Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Zacks Research raised shares of Pharma Mar to a “hold” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy”.

Pharma Mar Price Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The stock has a 50-day moving average price of $85.24 and a 200 day moving average price of $93.48.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.